` AUTL (Autolus Therapeutics PLC) vs S&P 500 Comparison - Alpha Spread

AUTL
vs
S&P 500

Over the past 12 months, AUTL has underperformed S&P 500, delivering a return of -44% compared to the S&P 500's +13% growth.

Stocks Performance
AUTL vs S&P 500

Loading
AUTL
S&P 500
Add Stock

Performance Gap
AUTL vs S&P 500

Performance Gap Between AUTL and GSPC
HIDDEN
Show

Performance By Year
AUTL vs S&P 500

Loading
AUTL
S&P 500
Add Stock

Competitors Performance
Autolus Therapeutics PLC vs Peers

S&P 500
AUTL
ABBV
AMGN
GILD
VRTX
Add Stock

Autolus Therapeutics PLC
Glance View

Market Cap
641.4m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
HIDDEN
Show
Back to Top